Meridian Bioscience (VIVO) Reports In-Line Q3 EPS, Miss on Revenues; Affirms Fiscal 2018 Guidance

Meridian Bioscience (NASDAQ: VIVO) reported Q3 EPS of $0.18, in-line with the analyst estimate of $0.18. Revenue for the quarter came in at $51.7 million versus the consensus estimate of $52.12 million.

FISCAL 2018 GUIDANCE REAFFIRMED

For the fiscal year ending September 30, 2018, management expects net revenues to be in the range of $209 million to $214 million, and non-GAAP net earnings per diluted share to be between $0.69 and $0.72 per share. Non-GAAP earnings per share for fiscal year 2018 excludes the impact of litigation costs, executive transition and realignment costs, potential future costs associated with the realignment of our organizational structure and the one-time benefit of tax reform, namely the re-measurement of deferred tax liabilities and the repatriation transition tax. Several of these excluded amounts pertain to events that have not yet occurred and are not currently possible to estimate with a reasonable degree of accuracy and could differ materially. Therefore, no reconciliation to GAAP amounts has been provided.

These per share estimates assume an increase in average shares outstanding from approximately 42.6 million at fiscal 2017 year-end to approximately 42.8 million at fiscal 2018 year-end.

The revenue and earnings guidance provided in this press release is derived from expected internal growth and does not include the impact of any acquisitions the Company may complete during fiscal 2018.

GUIDANCE:

Meridian Bioscience sees FY2018 EPS of $209.00-$214.00. Meridian Bioscience sees FY2018 revenue of $0.69-0.72 million.

For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.

You May Also Be Interested In

• IDT Corp. (IDT) Tops Q3 EPS by 2c; offer guidance
• Sprinklr (CXM) Tops Q1 EPS by 1c ; Offers Guidance
• Macy's (M) Tops Q1 EPS by 10c, Beats on Revenue; Offers FY27 Guidance